In the past week, GMAB stock has gone down by -2.95%, with a monthly decline of -13.01% and a quarterly plunge of -18.13%. The volatility ratio for the week is 1.81%, and the volatility levels for the last 30 days are 2.15% for Genmab ADR The simple moving average for the past 20 days is -5.47% for GMAB’s stock, with a -23.22% simple moving average for the past 200 days.
Is It Worth Investing in Genmab ADR (NASDAQ: GMAB) Right Now?
The price-to-earnings ratio for Genmab ADR (NASDAQ: GMAB) is above average at 18.20x, Company’s 36-month beta value is 1.01.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 2 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for GMAB is 635.13M, and currently, short sellers hold a 0.25% ratio of that floaft. The average trading volume of GMAB on February 12, 2025 was 1.36M shares.
GMAB) stock’s latest price update
Genmab ADR (NASDAQ: GMAB)’s stock price has soared by 0.03 in relation to previous closing price of 18.89. Nevertheless, the company has seen a loss of -2.95% in its stock price over the last five trading days. globenewswire.com reported 2025-02-12 that Company Announcement COPENHAGEN, Denmark; February 12, 2025 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024, financial performance for the year and the financial outlook for 2025.
Analysts’ Opinion of GMAB
Morgan Stanley, on the other hand, stated in their research note that they expect to see GMAB reach a price target of $31. The rating they have provided for GMAB stocks is “Equal-Weight” according to the report published on September 04th, 2024.
GMAB Trading at -8.78% from the 50-Day Moving Average
After a stumble in the market that brought GMAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.73% of loss for the given period.
Volatility was left at 2.15%, however, over the last 30 days, the volatility rate increased by 1.81%, as shares sank -12.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.68% lower at present.
During the last 5 trading sessions, GMAB fell by -2.93%, which changed the moving average for the period of 200-days by -31.17% in comparison to the 20-day moving average, which settled at $19.99. In addition, Genmab ADR saw -9.46% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GMAB
Current profitability levels for the company are sitting at:
- 0.31 for the present operating margin
- 0.96 for the gross margin
The net margin for Genmab ADR stands at 0.23. The total capital return value is set at 0.18. Equity return is now at value 14.67, with 12.34 for asset returns.
Based on Genmab ADR (GMAB), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at 6.82. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 124.26.
Currently, EBITDA for the company is 5.56 billion with net debt to EBITDA at -0.81. When we switch over and look at the enterprise to sales, we see a ratio of 4.14. The receivables turnover for the company is 3.13for trailing twelve months and the total asset turnover is 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.17.
Conclusion
In a nutshell, Genmab ADR (GMAB) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
